BCAT2 and melanoma: Although there were no significant differences on response rate between high and low BCAT2 group in GSE173839 (breast cancer), GSE135222 (NSCLC) and Gide 2019 cohort (melanoma), patients with low expression of BCAT2 were still more likely to have positive response to immunotherapy (Figure 7K–M).